Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Abpro Holdings, Inc. is a biotechnology company developing next-generation antibody therapeutics for immuno-oncology and ophthalmology. Utilizing proprietary DiversImmune® and MultiMab™ platforms, it engineers multi-specific antibodies, including its TetraBi format, to target diseases like HER2+ solid tumors and vascular eye disorders. The company advances a pipeline of antibody candidates through strategic global partnerships, focusing on improved efficacy, safety, and dosing convenience in large, unmet medical markets.
This description was generated via AI from an annual report. Updated about 1 year ago.